ClinicalTrials.gg
CompletedNCT05523687Updated Dec 20, 2022

AME Study of [14C]-PC14586 in Healthy Male Participants

A Phase 1 interventional study of [14C]-PC14586 in Healthy Male Volunteers, sponsored by PMV Pharmaceuticals, Inc. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-20.

Sponsored by PMV Pharmaceuticals, Inc · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Nov 2022, 3 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This study will assess the PK and rates of elimination and mass balance of total radioactivity from [14C]-PC14586

Read the detailed description

PC14586 is a first-in-class, oral, small molecule p53 reactivator that is selective for the TP53 Y220C mutation. The study will assess the PK, absorption, metabolism, and excretion of [14C]-PC14586 following a single dose in healthy male participants.

The aim is to recruit approximately 8 participants with a minimum number of 6 evaluable participants.

Each participant will be admitted to the study site pre-dose on Day -1 and will remain at the study site until at least Day 14. Participants will receive a single administration of [14C]-PC14586 as oral capsules on Day 1. During this study, whole blood, plasma, urine, feces, and vomit samples (if presented) will be collected at various timepoints to characterize the absorption, metabolism, excretion, and PK of [14C]-PC14586.

The duration of the residential period will be evaluated following the administration of [14C]-PC14586 and may be extended to ensure recovery of at least 90% of the total radioactivity, or until less than 1% of dose is recovered in urine and/or feces.

02

Conditions studied

  • Healthy Male Volunteers

Keywords

  • Y220C
  • PC14586
  • PMV Pharma
  • PMV
  • AME
03

In context

Lead sponsor

PMV Pharmaceuticals, Inc is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy, non-smoking males of any race, between 18 and 55 years of age, with between 18.0 and 32.0 kg/m2 inclusive.
  2. In good health, determined by no findings from medical history and evaluations at screening and check-in as assessed by the investigator.
  3. Agree to use a highly effective method of from check-in through 90 days after discharge.
  4. History of a minimum of 1 bowel movement per day.
  5. ≥90 mL/min determined using the Cockcroft-Gault equation.
  6. Able to swallow capsules.

Exclusion criteria

Exclusion Criteria:

  1. Significant history or clinical manifestation of any medical condition, disease or disorder, as determined by the investigator.
  2. Blood pressure >140 mm systolic or >90 diastolic at screening or Day -1.
  3. Positive hepatitis panel and/or positive test
  4. Use or intend to use any prescription and/or nonprescription medications/products within14 days prior to check-in.
  5. Participation in a clinical study involving last administration of an drug within the past 30 days prior to dosing, or within 5 half-lives of the IMP, whichever is longer, or who have participated in more than 3 radiolabeled drug studies in the last 12 months.
  6. Participants who have previously completed or withdrawn from this study or any other study investigating PC14586, or have previously received PC14586.
  7. Participants with a history of alcoholism or drug/chemical abuse within 2 years prior to check-in, use of tobacco or nicotine-containing products within 3 months prior to check-in or with a positive drug and/or alcohol test result at check-in.
  8. A positive p53 Y220C germline test at screening
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Single, oral dose of [14C]-PC14586

    Healthy, male participants will receive a single, oral dose of \[14C\]-PC14586

    Drug: [14C]-PC14586

Interventions

06

What researchers measure

Primary outcomes

  1. Characterize Maximum Plasma Concentration (Cmax) of PC14586 and PC14586 metabolite M1 (PC16163).

    Determine Cmax for PC14586 and PC16163 in plasma.

    Time frame: 1 month

  2. Characterize Time to Maximum Plasma Concentration (tmax) of PC14586 and PC14586 metabolite M1 (PC16163).

    Determine tmax for PC14586 and PC16163 in plasma.

    Time frame: 1 month

  3. Characterize Total Drug Exposure (AUC0-inf) of PC14586 and PC14586 metabolite M1 (PC16163).

    Determine AUC0-inf for PC14586 and PC16163 in plasma.

    Time frame: 1 month

  4. Characterize Total Drug Exposure to the last measurable concentration (AUC0-t) of PC14586 and PC14586 metabolite M1 (PC16163).

    Determine AUC0-t for PC14586 and PC16163 in plasma.

    Time frame: 1 month

  5. Characterize the Half-Life (t 1/2) of PC14586 and PC14586 metabolite M1 (PC16163).

    Determine t 1/2 for PC14586 and PC16163 in plasma.

    Time frame: 1 month

  6. Characterize the Clearance (CL/F) of PC14586 and PC14586 metabolite M1 (PC16163) after oral administration.

    Determine CL/F for PC14586 and PC16163 in plasma.

    Time frame: 1 month

  7. Characterize the Volume of Distribution (Vd/F) of PC14586 and PC14586 metabolite M1 (PC16163) after oral administration.

    Determine Vd/F for PC14586 and PC16163 in plasma.

    Time frame: 1 month

  8. Determine the total radioactivity in whole blood and plasma of PC14586 and PC14586 metabolite M1 (PC16163).

    Determine total radioactivity for PC14586 and PC16163 in whole blood and plasma.

    Time frame: 1 month

  9. Characterize total radioactivity (Xlast, feces) of PC14586 excreted in feces.

    Determine total radioactivity of PC14586 excreted in feces

    Time frame: 1 month

  10. Characterize the half life of total radioactivity (Xt1-t2, feces) of PC14586 excreted in feces.

    Determine half life of total radioactivity of PC14586 excreted in feces.

    Time frame: 1 month

  11. Characterize the fraction excreted of total radioactivity (fe last, feces) of PC14586 in feces.

    Determine the fraction excreted of total radioactivity of PC14586 in feces.

    Time frame: 1 month

  12. Characterize the half-life of fraction excreted of total radioactivity (fe t1-t2, feces) of PC14586 in feces.

    Determine half-life of fraction excreted of total radioactivity of PC14586 in feces.

    Time frame: 1 month

  13. Characterize total radioactivity (Xlast, urine) of PC14586 excreted in urine.

    Determine total radioactivity of PC14586 excreted in urine.

    Time frame: 1 month

  14. Characterize the half life of total radioactivity (Xt1-t2, urine) of PC14586 excreted in urine.

    Determine half life of total radioactivity of PC14586 excreted in urine.

    Time frame: 1 month

  15. Characterize the fraction excreted of total radioactivity (fe last, urine) of PC14586 in urine.

    Determine the fraction excreted of total radioactivity of PC14586 in urine.

    Time frame: 1 month

  16. Characterize the half-life of fraction excreted of total radioactivity (fe t1-t2, urine) of PC14586 in urine.

    Determine half-life of fraction excreted of total radioactivity of PC14586 in urine.

    Time frame: 1 month

  17. Characterize the renal clearance (CLr) of PC14586 in urine.

    Determine the renal clearance of PC14586 in urine.

    Time frame: 1 month

Secondary outcomes

  1. Identification of PC14586 metabolite profiles in plasma, urine and feces.

    Identification of PC14586 metabolites in plasma (\>10% relative total drug related exposure) and excreta (\>10% of excreted dose).

    Time frame: 1 month

  2. Identification of the incidence and severity of adverse events after administration of PC14586.

    Number of participants with adverse events.

    Time frame: 1 month

  3. Identification of the incidence of laboratory abnormalities based on hematology, clinical chemistry and urine test results of PC14586.

    Number of participants with an incidence of laboratory abnormalities in test results.

    Time frame: 1 month

  4. Identification of 12-lead electrocardiogram (ECG) abnormalities after a single dose of PC14586.

    Number of participants with abnormal 12-lead ECG results.

    Time frame: 1 month

  5. Identification of abnormal blood pressure after a single dose of PC14586.

    Number of participants with abnormal blood pressure.

    Time frame: 1 month

  6. Identification of abnormal pulse rate after a single dose of PC14586.

    Number of participants with abnormal pulse rate.

    Time frame: 1 month

  7. Identification of abnormal oral body temperature after a single dose of PC14586.

    Number of participants with abnormal oral body temperature.

    Time frame: 1 month

07

Study locations

1 site
  • Labcorp Clinical Research Unit Inc.
    Madison, Wisconsin 53704, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2022 to primary completion in Nov 2022, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2022
First posted
Aug 31, 2022
StartActual
Sep 6, 2022
Primary completionActual
Nov 30, 2022
CompletionActual
Nov 30, 2022
Last update
Dec 20, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05523687
Lead sponsor
PMV Pharmaceuticals, Inc
Responsible party
Sponsor
First posted
Aug 31, 2022
Start date
Sep 6, 2022
Primary completion
Nov 30, 2022
Completion
Nov 30, 2022
Last update
Dec 20, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rezatapopt

Start the discussion